ReviewMolecular psychiatry2012
Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.
Review in Molecular psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04923204 (Genetic Variations Associated With the Therapeutic Response and Profile of Adverse Effects in the Treatment of Bipolar Depression), which is not on this map. Cited by 103 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Variations Associated With the Therapeutic Response and Profile of Adverse Effects in the Treatment of Bipolar Depression
Who cites it
103 citing papers in PubMed, 4 syntheses or guidelines pooled it, 258 citations in OpenAlex.
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.The Cochrane database of systematic reviews · 2022Pooled it
- Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2016Pooled it
- Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample.The pharmacogenomics journal · 2016Pooled it
- A systematic review of antipsychotic drug effects on human gene expression related to risk factors for cardiovascular disease.The pharmacogenomics journal · 2014Pooled it
- Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study.Current neuropharmacology · 2022Trial
- Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole.Journal of psychiatric research · 2019Trial
- A rime-like Au-Pt nanostructured film and polyaniline-MIP based electrochemical sensor for olanzapine detection.Mikrochimica acta · 2026Article
- Decoding psychotropic-induced metabolic disturbances: gut-brain axis, multi-omics, and nutrition-lifestyle integration.Frontiers in nutrition · 2026Review
- Risk Factors and Management Strategies for Antipsychotic-Induced Weight Gain: A Prescriptive Review for Clinicians.Focus (American Psychiatric Publishing) · 2025Review
- GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.Nature metabolism · 2025Article
- Olanzapine and peripheral metabolic dysregulation: organ-resolved mechanisms, risk, and MASLD-aligned care pathways.Frontiers in pharmacology · 2025Review
- An in-depth exploration of the association between olanzapine, quetiapine and acute pancreatitis based on real-world datasets and network toxicology analysis.Frontiers in pharmacology · 2025Article
- Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.Molecular psychiatry · 2024Article
- "I Haven't Told Anyone but You": Experiences and Biopsychosocial Support Needs of People With Type 2 Diabetes and Binge Eating.Qualitative health research · 2024Article
- Relationship between functional connectivity and weight-gain risk of antipsychotics in schizophrenia.Schizophrenia research · 2024Article
- Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study.The pharmacogenomics journal · 2023Article
- The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics.Psychiatry investigation · 2023Article
- Association between Empathy and Clinical Symptoms among Overweight and Non-Overweight Chinese Chronic Schizophrenia Patients.Brain sciences · 2023Article
- Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.CNS drugs · 2023Review
- Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.Molecular psychiatry · 2023Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Second-generation antipsychotics (SGAs), such as risperidone, clozapine and olanzapine, are the most common drug treatments for schizophrenia. SGAs presented an advantage over first-generation antipsychotics (FGAs), particularly regarding avoidance of extrapyramidal symptoms. However, most SGAs, and to a lesser degree FGAs, are linked to substantial weight gain. This substantial weight gain is a leading factor in patient non-compliance and poses significant risk of diabetes, lipid abnormalities (that is, metabolic syndrome) and cardiovascular events including sudden death. The purpose of this article is to review the advances made in the field of pharmacogenetics of antipsychotic-induced weight gain (AIWG). We included all published association studies in AIWG from December 2006 to date using the Medline and ISI web of knowledge databases. There has been considerable progress reaffirming previous findings and discovery of novel genetic factors. The HTR2C and leptin genes are among the most promising, and new evidence suggests that the DRD2, TNF, SNAP-25 and MC4R genes are also prominent risk factors. Further promising findings have been reported in novel susceptibility genes, such as CNR1, MDR1, ADRA1A and INSIG2. More research is required before genetically informed, personalized medicine can be applied to antipsychotic treatment; nevertheless, inroads have been made towards assessing genetic liability and plausible clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.